NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
   

ProStrakan Group Announces Change of CFO
6/3/2009

Galashiels, Scotland, 3 June, 2009 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it is to appoint Allan Watson as its new Chief Financial Officer (“CFO”), replacing Paul Garvey, who has indicated to the Board of Directors his intention to step down from the position.

Allan (42), recently announced as Scottish Young Finance Director of the Year, will join ProStrakan, and its Board of Directors, later this year from medical technology company, Optos plc, where he has been CFO since 2003. A Pharmacy graduate, he has held a number of finance positions with companies both within and outside the healthcare sector since qualifying as an accountant.

Allan’s appointment follows the decision by Paul Garvey, ProStrakan’s CFO since 2007, to step down from the role following a period of ill health in 2008. Paul will continue in the role of CFO until Allan joins the Company later in the year.

Commenting on ProStrakan’s change of CFO, Dr Wilson Totten, Chief Executive, said:

“Paul Garvey has made a significant and valuable contribution to ProStrakan since he joined us in 2007 and I regret, as I know he does, that the period of ill health he suffered in 2008 has led him to step down now. I, and his colleagues on the Board and across the Company, wish him continued good health and future success.

“In Allan Watson we have attracted a highly regarded and professional CFO who has a deep understanding of the healthcare sector. His will be a pivotal role as the Company continues to work towards achieving break-even before the end of this year and profitability in 2010.”

Allan holds no further directorship positions and there are no other disclosures required under paragraphs 9.6.13 (1-6) of the FSA’s Listing Rules.

Galashiels, Scotland, 3 June, 2009 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it is to appoint Allan Watson as its new Chief Financial Officer (“CFO”), replacing Paul Garvey, who has indicated to the Board of Directors his intention to step down from the position.

Allan (42), recently announced as Scottish Young Finance Director of the Year, will join ProStrakan, and its Board of Directors, later this year from medical technology company, Optos plc, where he has been CFO since 2003. A Pharmacy graduate, he has held a number of finance positions with companies both within and outside the healthcare sector since qualifying as an accountant.

Allan’s appointment follows the decision by Paul Garvey, ProStrakan’s CFO since 2007, to step down from the role following a period of ill health in 2008. Paul will continue in the role of CFO until Allan joins the Company later in the year.

Commenting on ProStrakan’s change of CFO, Dr Wilson Totten, Chief Executive, said:

“Paul Garvey has made a significant and valuable contribution to ProStrakan since he joined us in 2007 and I regret, as I know he does, that the period of ill health he suffered in 2008 has led him to step down now. I, and his colleagues on the Board and across the Company, wish him continued good health and future success.

“In Allan Watson we have attracted a highly regarded and professional CFO who has a deep understanding of the healthcare sector. His will be a pivotal role as the Company continues to work towards achieving break-even before the end of this year and profitability in 2010.”

Allan holds no further directorship positions and there are no other disclosures required under paragraphs 9.6.13 (1-6) of the FSA’s Listing Rules.

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is situated in Galashiels in Scotland. The company’s development capabilities are centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries. www.prostrakan.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES